HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients

Table 3 Univariate and multivariate modeling of baseline and selected on-treatment characteristics

Characteristics	CR (+)
	Univariate		Multivariate
	OR (95 % CI)	p value	OR (95 % CI)	p value
Age	0.96 (0.91, 1.01)	0.14
Gender (Male)	0.81 (0.34, 1.91)	0.62
BMI	0.98 (0.87, 1.10)	0.72
HBV Genotype (B)	0.88 (0.41, 1.89)	0.74
ALT (*ULN)	1.19 (1.00, 1.43)	0.05
ALT > 5*ULN	1.97 (0.83, 4.64)	0.12
HBsAg (Log₁₀ IU/mL)	0.41 (0.22, 0.79)	0.01	0.38 (0.19, 0.79)	0.01
HBeAg (Log₁₀ IU/mL)	0.61 (0.34, 1.08)	0.09
HBV DNA (Log₁₀ IU/mL)	0.83 (0.51, 1.33)	0.43
On-treatment Quantifications, week 12
HBsAg decrease > 1.5Log	3.34 (0.99, 11.30)	0.05	3.36 (0.90, 12.56)	0.07
HBeAg decrease > 1.5Log	2.88 (1.30, 6.36)	0.01
HBV DNA decrease > 2.0Log	3.82 (1.73, 8.40)	<0.01
On-treatment Quantifications, week 24
HBsAg decrease > 1.5Log	2.57 (1.06, 6.19)	0.04
HBeAg decrease > 1.5Log	4.60 (2.02 10.47)	<0.01	4.02 (1.72, 9.39)	<0.01
HBV DNA decrease > 2.0Log	4.28 (1.85, 9.90)	<0.01

All baseline and selected on-treatment characteristics were analyzed for CR (N = 171) by univariate analysis and were all entered into multivariate model where variables with p < 0.1 were retained by Hierarchical Forward with Switching Method

ISSN: 1743-422X